glycine has been researched along with Angiohemophilia in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Platelet-type von Willebrand disease (plt-VWD) is a congenital bleeding disorder characterized by gain-of-function mutations of GPIbalpha." | 1.32 | Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. ( Ikeda, Y; Matsubara, Y; Murata, M; Sugita, K, 2003) |
| "Type 2A is a qualitative variant of von Willebrand disease (vWD) characterized by a reduced platelet-dependent function, associated with an absence of large multimers." | 1.30 | Identification of a new candidate mutation, G1629R, in a family with type 2A von Willebrand disease. ( Aznar, JA; Casaña, P; Haya, S; Martínez, F, 1999) |
| "Platelet-type von Willebrand disease (PT-vWD) is an autosomal dominant bleeding disorder in which patient platelets exhibit an abnormally increased binding of circulating von Willebrand factor (vWF)." | 1.28 | Conformational energy analysis of the substitution of Val for Gly 233 in a functional region of platelet GPIb alpha in platelet-type von Willebrand disease. ( Carty, RP; Dykes, DC; Miller, JL; Pincus, MR, 1991) |
| "Treatment of von Willebrand disease with two plasma antihemophilic factor (AHF) concentrates, cryoprecipitate and glycine-precipitated AHF, was compared." | 1.26 | Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. ( Blatt, PM; Brinkhous, KM; Culp, HR; Krauss, JS; Roberts, HR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsubara, Y | 1 |
| Murata, M | 2 |
| Sugita, K | 1 |
| Ikeda, Y | 1 |
| Nurden, P | 1 |
| Lanza, F | 1 |
| Bonnafous-Faurie, C | 1 |
| Nurden, A | 1 |
| Donnér, M | 1 |
| Kristoffersson, AC | 1 |
| Berntorp, E | 1 |
| Scheibel, E | 1 |
| Thorsen, S | 1 |
| Dahlbäck, B | 1 |
| Nilsson, IM | 1 |
| Holmberg, L | 1 |
| Russell, SR | 1 |
| Ruggeri, ZM | 1 |
| Ware, J | 1 |
| Hagiwara, T | 1 |
| Inaba, H | 1 |
| Yoshida, S | 1 |
| Nagaizumi, K | 1 |
| Arai, M | 1 |
| Hanabusa, H | 1 |
| Fukutake, K | 1 |
| Gu, J | 1 |
| Jorieux, S | 1 |
| Lavergne, JM | 1 |
| Ruan, C | 1 |
| Mazurier, C | 1 |
| Meyer, D | 1 |
| Song, KS | 1 |
| Kang, SH | 1 |
| Kang, MS | 1 |
| Park, YS | 1 |
| Choi, JR | 1 |
| Kim, HK | 1 |
| Park, Q | 1 |
| Casaña, P | 1 |
| Martínez, F | 1 |
| Haya, S | 1 |
| Aznar, JA | 1 |
| Legaz, ME | 1 |
| Weinstein, MJ | 1 |
| Heldebrant, CM | 1 |
| Davie, EW | 1 |
| Blatt, PM | 1 |
| Brinkhous, KM | 1 |
| Culp, HR | 1 |
| Krauss, JS | 1 |
| Roberts, HR | 1 |
| Pincus, MR | 1 |
| Dykes, DC | 1 |
| Carty, RP | 1 |
| Miller, JL | 1 |
| Rossman, RE | 1 |
| Brody, JI | 1 |
| Breckenridge, RT | 1 |
| Ratnoff, OD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
2 reviews available for glycine and Angiohemophilia
| Article | Year |
|---|---|
Isolation, subunit structure, and proteolytic modification of bovine factor VIII.
Topics: Aminocaproates; Anticoagulants; Blood Coagulation Tests; Calcium; Carbohydrates; Cellulose; Chromato | 1975 |
Therapy of hereditary disorders of blood coagulation.
Topics: Abdomen, Acute; Afibrinogenemia; Blood Coagulation Disorders; Blood Transfusion; Cerebral Hemorrhage | 1968 |
11 other studies available for glycine and Angiohemophilia
| Article | Year |
|---|---|
Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease.
Topics: Bleeding Time; Blood Platelets; Blood Proteins; Cell Line; Child, Preschool; Dose-Response Relations | 2003 |
A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene.
Topics: Adult; Blood Platelet Disorders; Blood Platelets; Female; Glycine; Humans; Mutation; Platelet Functi | 2007 |
Two new candidate mutations in type IIA von Willebrand's disease (Arg834-->Gly, Gly846-->Arg) and one polymorphism (Tyr821-->Cys) in the A2 region of the von Willebrand factor.
Topics: Adolescent; Adult; Alleles; Amino Acid Sequence; Arginine; Base Sequence; Child; Cysteine; DNA; Fema | 1993 |
Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.
Topics: Amino Acid Sequence; Animals; Blood Platelets; CHO Cells; Cricetinae; Crotalid Venoms; Genetic Varia | 1993 |
A novel mutation Gly 1672-->Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease.
Topics: Arginine; Asian People; Case-Control Studies; DNA; DNA Mutational Analysis; Exons; Glycine; Homozygo | 1996 |
A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies.
Topics: Adult; Aged; Alleles; Animals; Antibodies, Monoclonal; COS Cells; DNA Primers; Exons; Female; Geneti | 1997 |
von Willebrand disease with G4022A mutation (vWd Sungnam): a case report.
Topics: Alanine; Child; Glycine; Humans; Male; Point Mutation; von Willebrand Diseases; von Willebrand Facto | 1999 |
Identification of a new candidate mutation, G1629R, in a family with type 2A von Willebrand disease.
Topics: Arginine; Base Sequence; Deoxyribonucleases, Type II Site-Specific; Female; Glycine; Humans; Male; M | 1999 |
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.
Topics: Antigens; Blood Coagulation Disorders; Blood Coagulation Tests; Chemical Precipitation; Factor VIII; | 1976 |
Conformational energy analysis of the substitution of Val for Gly 233 in a functional region of platelet GPIb alpha in platelet-type von Willebrand disease.
Topics: Amino Acid Sequence; Blood Platelets; Computer Simulation; Glycine; Humans; Macromolecular Substance | 1991 |
Reactivity to factor-VIII concentrates of lymphocytes from patients with haemophilia and von Willebrand's disease.
Topics: Adolescent; Adult; Albumins; Antigens; Carbon Radioisotopes; Cells, Cultured; Chemical Precipitation | 1974 |